About 41% and 30% of patients with chronic spontaneous urticaria (CSU), respectively, achieved well-controlled disease status and complete response when treated with dupilumab.
ACAAI Annual Scientific Meeting - American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
Evolving Strategies for RSV Prevention in Infants
2
Etentamig Shows Manageable Safety and Low Severe Infection Risk in RRMM
3
FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Psoriatic Arthritis
4
Fun Fact: Researchers Crack the Myth of High Cholesterol and Eggs
5
